Current status and future perspectives for the treatment of resectable locally advanced esophagogastric junction cancer: A narrative review

Table 3 Clinical trials of neoadjuvant therapy for esophagogastric junction cancer included in this review

Study name	FLOT4[3,32]	CROSS[4,33]	PRODIGY[34]
Ref.	Al-Batran et al[3,32]	Shapiro et al[33], van Hagen et al[4]	Kang et al[34]
Year	2016/2019	2012/2015	2021
Study design	Phase II/III	Phase III	Phase III
Eligible patients	cT2-4 and/or cN+, cM0	cT1N+ or cT2-3, cM0	cT2-3N+ or cT4, cM0
	Gastric or EGJ cancer	Esophageal or EGJ cancer	Gastric or EGJ cancer
Experimental arm	FLOT	CBDCA + PTX + RT	DOS + adjuvant S1
Control arm	ECF/ECX	Surgery alone	Adjuvant S1
Total number of patients	716	366	484
EGJ cancer patients	56%	24%	6%
Primary outcome	OS	OS	Progression free survival
OS	50 vs 35 mo	48.6 vs 24.0 mo	NA
pCR rate	16% vs 6%	29%	10.40%
R0 resection rate	85% vs 78%	92% vs 69%	89% vs 84%
Special notes	Effective for EGJ cancer		Progression free survival, 66.3 months vs 60.2 months. Equivalent OS. Small population of EGJ cancer patients (27 patients)

EGJ: Esophagogastric junction; pCR: Pathological complete response; FLOT: 5-fluorouracil + leucovorin + oxaliplatin + docetaxel; ECF: Epirubicin + cisplatin + 5-fluorouracil; ECX: Epirubicin + cisplatin + capecitabine; CBDCA: Carboplatin; PTX: Paclitaxel; RT: Radiation therapy; DOS: Docetaxel + oxaliplatin + S-1; NA: Not available; OS: Overall survival.